Locally advanced disease has progressed within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy urothelial carcinoma (UC)
Locally advanced Urothelial Carcinoma: Progression After Neoadjuvant or Adjuvant Platinum-Containing Chemotherapy
Urothelial carcinoma (UC) is a type of cancer that forms in the tissue layers of the Urinary Tract system. It commonly develops within the bladder as well as other parts of the Urinary Tract system, such as the kidneys, ureters, and urethra. It is the most common type of bladder cancer, accounting for 90% of all cases.
When UC is locally advanced, surgery is not typically recommended and neoadjuvant or adjuvant treatment with platinum-containing chemotherapy is usually preferred. However, over time, Advanced Urothelial Cancer (AUC) can progress in spite of this type of therapy. This progression is what has made understanding the right treatment protocol and achieving better patient outcomes a challenge. Recent research has investigated the progression of AUC after neoadjuvant and/or adjuvant treatment with platinum-containing chemotherapy.
Recent Data on Progression of Advanced Urothelial Cancer
Recent data has found that within 12 months of completing neoadjuvant and/or adjuvant treatment with platinum-containing chemotherapy, AUC has a high rate of progression. Out of a study group of 1,593 patients, it was found that 33.2% of patients experienced progression after one year. Additionally, out of the 383 patients who experienced progression, 84.5% of them occurred within 12-months of completing neoadjuvant and/or adjuvant therapy.
Factors Contributing to AUC Progression
The study also identified some factors that may have contributed to the progression of AUC. These factors included:
- Smoking history
- Stage at diagnosis
- Pathologic complete response to neoadjuvant/adjuvant chemotherapy
- Number of chemotherapy cycles
- Body Mass Index (BMI)
It should be noted, however, that the exact cause of progression of AUC is still unclear. Further research is needed to better understand which factors may be contributing to its progression.
Conclusion
Urothelial carcinoma is a type of cancer that most commonly develops within the bladder. When it is locally advanced, neoadjuvant or adjuvant treatment with platinum-containing chemotherapy is typically recommended. Recent data has found that within 12 months of completing this type of treatment, AUC can progress at a high rate. Additionally, some factors have been identified that may be contributing to its progression including smoking, body mass index, stage at diagnosis, and more. Further research is needed to better understand cause of progression.